Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis

• Published in: Archives of osteoporosis Vol. 18; no. 1; p. 42
• Main Authors: Singer, A., McClung, M. R., Tran, O., Morrow, C. D., Goldstein, S., Kagan, R., McDermott, M., Yehoshua, A.
• Format: Journal Article
• Language: English
• Published: London Springer London 11.03.2023
• Subjects: Aged; Bone Density Conservation Agents - therapeutic use; Data Analysis; Endocrinology; Female; Health Care Costs; health services; hospitals; Humans; Medicare; Medicine; Medicine & Public Health; Original; Original Article; Orthopedics; osteoporosis; Osteoporosis - drug therapy; Osteoporotic Fractures; Retrospective Studies; therapeutics; United States; United States; Postmenopausal; Health care costs; Cost of illness; Medicare; Humans; Hospitalization; Bone density/drug effects; Bone density conservation agents; Middle aged; Risk assessment; Female; Aged; USA/epidemiology
• ISSN: 1862-3514; 1862-3522; 1862-3514
• DOI: 10.1007/s11657-023-01229-7

Summary In a characterization of treatment rates and healthcare costs among patients with an osteoporotic-related fragility fracture overall and by site of care, costs were high and treatment rates were low. Purpose Osteoporotic fractures can be debilitating, even fatal, among older adults. The cost of osteoporosis and related fractures is projected to increase to more than $25 billion by 2025. The objective of this analysis is to characterize disease-related treatment rates and healthcare costs of patients with an osteoporotic fragility fracture overall and by site of fracture diagnosis. Methods In this retrospective analysis, individuals with fragility fractures were identified in the Merative MarketScan® Commercial and Medicare Databases among women 50 years of age or older and diagnosed with fragility fracture between 1/1/2013 and 6/30/2018 (earliest fracture diagnosis = index). Cohorts were categorized by clinical site of care where the diagnosis of fragility fracture was made and were continuously followed for 12 months prior to and following index. Sites of care were inpatient admission, outpatient office, outpatient hospital, emergency room hospital, and urgent care. Results Of the 108,965 eligible patients with fragility fracture (mean age 68.8), most were diagnosed during an inpatient admission or outpatient office visit (42.7%, 31.9%). The mean annual healthcare costs among patients with fragility fracture were $44,311 (± $67,427) and were highest for those diagnosed in an inpatient setting ($71,561 ± $84,072). Compared with other sites of care at fracture diagnosis, patients diagnosed during an inpatient admission also had highest proportion of subsequent fractures (33.2%), osteoporosis diagnosis (27.7%), and osteoporosis therapy (17.2%) during follow-up. Conclusion The site of care for diagnosis of fragility fracture affects treatment rates and healthcare costs. Further studies are needed to determine how attitude or knowledge about osteoporosis treatment or healthcare experiences differ at various clinical sites of care in the medical management of osteoporosis.